Clinical Progress and Surging Sales Drive Investor Confidence in ImmunityBio

ImmunityBio stock surges 345% YTD as cancer drug ANKTIVA revenue jumps 700%. Key FDA submissions for bladder cancer and bullish analyst upgrades drive investor optimism.

ImmunityBio's stock is experiencing a significant rally, fueled by a powerful combination of robust commercial performance and promising developments in its clinical pipeline. Investor attention is increasingly fixed on two key regulatory processes with the U.S. Food and Drug Administration (FDA), which have the potential to substantially expand the biotechnology firm's market opportunity.

The company's shares surged nearly ten percent in a single trading session this Monday. This latest gain contributes to an extraordinary year-to-date increase of 345 percent. This investor optimism is grounded in concrete financial results. For the full fiscal year 2025, net product revenue for its cancer drug ANKTIVA skyrocketed by approximately 700 percent to $113 million. Furthermore, fourth-quarter performance exceeded analyst forecasts, with revenue reaching $38.28 million and a per-share loss of just $0.06.

Pipeline Advancements Underpin Growth Strategy

Beyond commercial execution, ImmunityBio is achieving critical milestones in clinical development. A primary focus is the pivotal QUILT-2.005 study for bladder cancer treatment, where patient recruitment concluded ahead of schedule. Nine-month interim data demonstrated statistically significant superiority: a complete response was observed in 84 percent of patients receiving the ANKTIVA combination therapy, compared to 52 percent of those on the standard of care.

Leveraging these compelling results, the company's management is preparing to submit a supplemental Biologics License Application (BLA) in the fourth quarter of 2026. In a separate but related move, ImmunityBio filed for an additional bladder cancer indication with the FDA in early March. The therapy's recent inclusion in the updated National Comprehensive Cancer Network (NCCN) treatment guidelines is expected to further bolster its adoption within the medical community.

Financial Backing and Upcoming Catalysts

With a solid cash position of $242.8 million, ImmunityBio is well-funded to advance its development plans. The immediate focus for markets now shifts to the planned fourth-quarter regulatory submission and the ongoing FDA review of documentation already filed. These forthcoming regulatory decisions are poised to be key determinants of the company's commercial trajectory in the near term.

Market Analysts Revise Targets Upward

The strengthened fundamentals and accelerating revenue growth have prompted several Wall Street firms to reassess their outlooks for ImmunityBio:

• Piper Sandler: Upgraded its rating to Overweight, raising its price target from $7 to $12. The firm projects U.S. net sales for ANKTIVA to reach $195 million this year.
• BTIG: Maintained a Buy recommendation with a $13 price target. Analysts highlighted the potential value of future planned studies, including those in non-small cell lung cancer (NSCLC).

The convergence of strong sales, decisive clinical data, and a clear path toward regulatory milestones continues to build a compelling narrative for ImmunityBio, capturing the attention of growth-focused investors.